While both bluebird bio (NASDAQ: BLUE) and Inovio Pharmaceuticals (NASDAQ: INO) started out 2016 poorly, the paths of the two biotech stocks have diverged greatly since late January. Bluebird’s stock price is down over 30% year to date, but Inovio’s shares are up nearly 60%.